Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

These abstracts and posters will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will be held Feb. 26-28 at the Moscone West Conference Center, ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

Pathologic re-review of NMIBC surgical specimens by genitourinary pathologists led to a change in risk stratification in one-fifth of cases. Pathologic re-review of transurethral resection of bladder ...

Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...

This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...

Spouses and first-degree relatives of patients with genitourinary (GU) cancers face increased risks of developing cardiovascular and psychological comorbidities, particularly within the first year of ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that ...